Advertisement

The risk of recurrent venous thromboembolic disease — implications for treatment

  • S. Eichinger
  • P. A. Kyrle
  • I. Pabinger
  • K. Lechner
Chapter
  • 85 Downloads

Summary

Patients with venous thromboembolism are at risk of recurrent thrombosis. Since this risk is particularly high within the first weeks and months after the acute event, intensive heparin treatment followed by oral anticoagulants for at least 3 to 6 months is generally recommended. After discontinuation of secondary thromboprophylaxis, the cumulative incidence of recurrence still remains high (approximately 20 % after 5 years).

Patients at risk of recurrence may be identified by evaluation of clinical and/or laboratory findings. Patients with cancer, the antiphospholipid antibody (APLA) syndrome, patients with antithrombin-, protein C- or protein S-deficiency, or patients with hyperhomocysteinemia are at an especially high risk of recurrent thrombosis. In patients with the factor V Leiden mutation or the G20210A variant in the prothrombin gene, data on the recurrence rate are currently controversial or unknown.

While a massive activation of coagulation and fibrinolysis is observed during and after an acute venous thromboembolic event, monitoring of coagulation activation markers, such as prothrombin fragment F1 + 2, has not proven helpful for prediction of recurrence.

Since the risks of secondary thromboprophylaxis (mainly bleeding) have to be weighed against the benefit in terms of prevention of recurrence, it is common practice to discontinue oral anticoagulants after 6 months. However, some patients have an increased risk of recurrence, and prolonged secondary thromboprophylaxis should be considered. Although randomized trials to compare different treatment modalities in patients at high risk of recurrence are currently lacking, we suggest that after a first or second venous thromboembolic event patients with cancer, with an APLA-syndrome, patients with type I antithrombin deficiency, patients with combined deficiencies and probably patients with hyperhomocysteinemia are candidates for secondary thromboprophylaxis beyond 6 months. The presence of factor V Leiden alone does not justify secondary thromboprophylaxis longer than 6 months.

Key words

Venous thromboembolism recurrence treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dahlbäck B (1995) Inherited thrombophilia: resistance to activated protein C as a pathogenetic factor of venous thrombosis. Blood 85:607–614PubMedGoogle Scholar
  2. 2.
    d’Angelo A, Selhub J (1997) Homocysteine and thrombotic disease. Blood 90:1–11Google Scholar
  3. 3.
    de Stefano V, Finazzi G, Mannucci PM (1996) Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 87:3531–3544PubMedGoogle Scholar
  4. 4.
    Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Minar E, Lechner K, Kyrie PA (1997) The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 77:624–628PubMedGoogle Scholar
  5. 5.
    Eichinger S, Stümpflen A, Hirschl M, Bialonczyk C, Pabinger I, Herkner K, Schneider B, Lechner K, Kyrie PA (1997) Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism in male patients. Thromb Haemost (Suppl): 184Google Scholar
  6. 6.
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997PubMedCrossRefGoogle Scholar
  7. 7.
    Kyrie PA, Eichinger S, Pabinger I, Stümpflen A, Hirschl M, Bialonczyk C, Schneider B, Mannhalter C, Melichart M, Traxler G, Weltermann A, Speiser W, Lechner K (1997) Prothrombin fragment F1 + 2 is not predictive for recurrent venous thromboembolism. Thromb Haemost 77:829–833Google Scholar
  8. 8.
    Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U (1996) Inherited thrombophilia: Part 1. Thromb Haemost 76: 651–662PubMedGoogle Scholar
  9. 9.
    Levine MN, Hirsh J, Landefeld S, Raskob G (1992) Hemorrhagic complications of anticoagulant treatment. Chest 102 (Suppl): 352–363Google Scholar
  10. 10.
    Pabinger I, Brücker S, Kyrie PA, Schneider B, Korninger HC, Niessner H, Lechner K (1992) Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 3: 547–553PubMedCrossRefGoogle Scholar
  11. 11.
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-translated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMedGoogle Scholar
  12. 12.
    Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7PubMedGoogle Scholar
  13. 13.
    Research Committee of the British Thoracic Society (1992) Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 340:783–876CrossRefGoogle Scholar
  14. 14.
    Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH (1995) Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 92:2800–2802PubMedGoogle Scholar
  15. 15.
    Sarasin FP, Bounameaux H (1994) Duration of oral anticoagulant therapy after proximal deep vein thrombosis: A decision analysis. Thromb Haemost 71:286–291PubMedGoogle Scholar
  16. 16.
    Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Kjell-Ake J, Hjorth M, Linder O, Boberg J, and the Duration of Anticoagulation Trial Study Group (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 332:1661–1665PubMedCrossRefGoogle Scholar
  17. 17.
    Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A (1997) The risk of recurrent venous thromboembolism in patients with an Arg506 → Gin mutation in the gene for factor V (factor V Leiden). N Engl J Med 336: 399–403PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 2000

Authors and Affiliations

  • S. Eichinger
    • 1
  • P. A. Kyrle
    • 1
  • I. Pabinger
    • 1
  • K. Lechner
    • 1
  1. 1.Division of Haematology and HaemostaseologyDepartment of Medicine IWienAustria

Personalised recommendations